论文部分内容阅读
目的评价氯沙坦钾治疗原发性高血压合并高尿酸血症患者的临床疗效。方法随机选择原发性高血压合并高尿酸血症患者66例,给予氯沙坦钾50 mg/d为起始剂量,根据血压及血尿酸水平调整使用剂量,在治疗前1 d,治疗后6、12周分别测量血压及血尿酸水平,观察入组患者的血压、尿酸及不良反应情况。结果入选患者在治疗前后血压均下降平稳,达至治疗目标值,治疗6周后血尿酸有不同程度的降低,12周后血尿酸均降至正常范围。整个治疗过程中未出现干咳、低血压、电解质紊乱等不良反应,未发现肝肾功能损伤及糖脂代谢紊乱。结论氯沙坦钾治疗原发性高血压安全、有效,不良反应发生率低,更能有效降低血尿酸水平,有助于控制痛风发作。
Objective To evaluate the clinical efficacy of losartan potassium in patients with essential hypertension complicated with hyperuricemia. Methods Sixty-six patients with essential hypertension and hyperuricemia were randomly selected. Losartan 50 mg / d was used as the initial dose, and the dosage was adjusted according to blood pressure and serum uric acid level. One day before treatment and 6 Blood pressure and serum uric acid levels were measured at 12 weeks. The blood pressure, uric acid and adverse reactions of the patients were observed. Results Before and after treatment, the blood pressure of the selected patients decreased smoothly and reached the therapeutic target value. After 6 weeks of treatment, the blood uric acid decreased to some extent. After 12 weeks, the blood uric acid dropped to the normal range. The entire course of treatment did not appear dry cough, hypotension, electrolyte disorders and other adverse reactions, no liver and kidney damage and glucose and lipid metabolism disorders. Conclusion Losartan potassium in the treatment of essential hypertension is safe and effective, the incidence of adverse reactions is low, more effective in lowering serum uric acid levels, help to control gout attacks.